EUVIMEDEUVIMED entdecken
Crossref

Real‐world use of cenobamate in adults: Efficacy and predictors of treatment response

Itai Loushy iD, Lilach Goldstein iD, Kathryn Devlin, Anna Volski, Elizabeth Fletman, Juan Luis Alcala-Zermeno iD, Louis Porreca, Michael R Sperling iD

Epilepsia · 2025

DOI: 10.1111/epi.18297 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, 2025. Verfasst von Itai Loushy und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Anticonvulsants, Carbamates, Chlorophenols, Seizures. Die Arbeit wurde bisher 26-mal zitiert (Crossref) und nennt 49 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study assesses the efficacy, safety, and tolerability of cenobamate using long‐term real‐world data, incorporating both seizure reduction and seizure‐freedom periods, and examines baseline clinical variables to determine predictors of response.

Methods

We retrospectively analyzed all patients prescribed cenobamate from May 2020 to July 2021. The primary outcome was 12‐month seizure frequency reduction for each seizure type, stratified by baseline seizure frequency (higher vs lower frequency: ≥2 seizures vs

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsCarbamatesChlorophenolsSeizuresEpilepsies, PartialHumansMaleFemaleMiddle AgedRetrospective StudiesAdultTreatment OutcomeAgedYoung AdultTetrazoles

Stichwörter der Autor:innen

anti‐seizure medicationscenobamatedrug‐resistant epilepsyfocal seizuresreal‐world

Substanzen

AnticonvulsantsCenobamateCarbamatesChlorophenolsTetrazoles

Autor:innen und Institutionen

  • Department of Neurology, Jefferson Comprehensive Epilepsy Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
  • EEG and Epilepsy Unit, Department of Neurology, Tel Aviv Sourasky Medical Center (TASMC), Tel Aviv, Israel.
  • Department of Neurology, Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Department of Psychological and Brain Sciences, Drexel University, Philadelphia, Pennsylvania, USA.
  • Department of Neurology, Columbia University Medical Center, New York, New York, USA.

ORCID-Profile: Itai Loushy, Lilach Goldstein, Juan Luis Alcala-Zermeno, Michael R Sperling

Zitieren

APA

Loushy, I., Goldstein, L., Devlin, K., Volski, A., Fletman, E., Alcala-Zermeno, J. L., Porreca, L., & Sperling, M. R. (2025). Real‐world use of cenobamate in adults: Efficacy and predictors of treatment response. Epilepsia. https://doi.org/10.1111/epi.18297

Vancouver

Loushy I, Goldstein L, Devlin K, Volski A, Fletman E, Alcala-Zermeno JL, et al. Real‐world use of cenobamate in adults: Efficacy and predictors of treatment response. Epilepsia. 2025. doi:10.1111/epi.18297

BibTeX
@article{Loushy2025,
  author = {Loushy, Itai and Goldstein, Lilach and Devlin, Kathryn and Volski, Anna and Fletman, Elizabeth and Alcala-Zermeno, Juan Luis and Porreca, Louis and Sperling, Michael R},
  title = {Real‐world use of cenobamate in adults: Efficacy and predictors of treatment response},
  journal = {Epilepsia},
  year = {2025},
  doi = {10.1111/epi.18297}
}
Kostenlos starten →